IMBRAVE150-(UPDATED)

NCT03434379 📎

Regimen

Experimental
atezolizumab + bevacizumab
Control
sorafenib

Population

Unresectable hepatocellular carcinoma, no prior systemic therapy (updated analysis, +12 mo follow-up)

Key finding

Updated mOS 19.2 vs 13.4 mo (HR 0.66, 95% CI 0.52-0.85); mPFS 6.9 vs 4.3 mo (HR 0.65, 95% CI 0.53-0.81); confirms durability of benefit at ~15.6 mo median follow-up

Source: PMID 34902530

Timeline

    Guideline citations

    • NCCN HCC (p.28)